Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

AI Agents Enter Regulated Workflows; Penn Medicine Starts a New Healthcare Shift – Copy

Compass Pathways has reported new six-month Phase III data showing that its psilocybin-based therapy, COMP360, continued to provide durable clinical benefits for patients with treatment-resistant depression. While the efficacy results attracted attention, the announcement also moves the therapy closer to
  • News
COMP360 Nears FDA Approval; Validation Requirements May Soon Change

Pharmaceutical Warehouse in 2026: GMP Storage Requirements and Inspection Readiness

Discover how compliant pharmaceutical storage supports product quality, regulatory compliance, and inspection readiness. This guide explains warehouse controls, temperature mapping, environmental monitoring, cold chain management, and practical strategies that help reduce inspection findings while maintaining product integrity throughout the supply
  • Blog, Validation and Qualification

AI Agents Enter Regulated Workflows; Penn Medicine Starts a New Healthcare Shift

Penn Medicine has integrated K Health’s AI-powered patient intake agents into its virtual primary care service, marking another step toward embedding AI agents into regulated clinical workflows. Rather than replacing clinicians, the system gathers patient information before appointments and delivers
  • News
AI Agents Enter Regulated Workflows; Penn Medicine Starts a New Healthcare Shift

Regulatory Compliance Consulting in 2026: FDA, EMA, and Regulatory Affairs

Discover how pharmaceutical regulatory consulting helps organizations eliminate common GMP compliance gaps, improve FDA Compliance and EMA Compliance, implement ICH Guidelines, strengthen regulatory strategy, and achieve greater inspection readiness for successful global market authorization.
  • Blog, Quality Management System
Infographic illustrating common GMP inspection gaps, including documentation, CAPA, data integrity, change control, and risk management that support regulatory consulting services, FDA Compliance, EMA Compliance, and ICH Guidelines.

Boston Is Losing Its Edge; Three Unexpected Cities Are Winning Pharma Investment

New pharmaceutical manufacturing investments are beginning to reshape the U.S. biotech landscape beyond traditional hubs like Boston and Cambridge. According to a report by Alexandra Pecci published on July 6, Lancaster County, Oklahoma City and Las Vegas are attracting major
  • News
Boston Is Losing Its Edge; Three Unexpected Cities Are Winning Pharma Investment

CMS Raises Outpatient Payments; 340B Cuts Could Rewrite Hospital Drug Economics

The Centers for Medicare & Medicaid Services (CMS) has released its proposed 2027 Hospital Outpatient Prospective Payment System rule, introducing a 2.4% outpatient payment increase while proposing significant reductions in the 340B Drug Pricing Program reimbursement and expanding site-neutral payment
  • News
CMS Raises Outpatient Payments; 340B Cuts Could Rewrite Hospital Drug Economics

Pharma GMP Consultant in 2026: GMP Consulting, FDA Readiness, and Compliance

Discover how GMP consulting services help pharmaceutical companies strengthen quality management systems, improve validation, enhance FDA inspection readiness, and reduce compliance risks through practical, risk-based strategies that support sustainable regulatory success across the entire product lifecycle.
  • Blog, Quality Management System
Pharmaceutical quality specialists reviewing manufacturing operations as part of GMP compliance consulting, validation activities, and FDA inspection readiness in a modern GMP facility.

Earlier Malignancy Signals Challenged Obefazimod; New Phase III Data Strengthens NDA Path

Abivax has reported new Phase III maintenance data showing that obefazimod maintained a favorable benefit-risk profile in adults with moderate to severe ulcerative colitis, despite safety concerns raised only weeks earlier. The updated findings strengthen the company's planned New Drug
  • News
Earlier Malignancy Signals Challenged Obefazimod; New Phase III Data Strengthens NDA Path